

**PRESS RELEASE PRESS RELEASE PRESS RELEASE PRESS RELEASE**

**Trexel Contact:**

David Bernstein  
President & CEO  
Trexel, Inc.  
USA +1 781-932-0202, Ext. 239  
[d.bernstein@trexel.com](mailto:d.bernstein@trexel.com)

**Trexel GmbH Contact:**

Dr. Hartmut Traut  
Business Director  
Trexel GmbH  
+49-2261-814-145  
[h.traut@trexel.com](mailto:h.traut@trexel.com)

**Trexel Licenses First Optifoam® User in Europe**

*License seen as important step towards clarifying patent situation*

**September 15, 2005 Woburn, MA.** Trexel Inc., developers of the MuCell® Microcellular Foam Process, has announced that it has provided a patent only license to the first commercial Optifoam customer of Sulzer Chemtech in Europe. While the details of the license are confidential, the license not only provides global rights under Trexel Patents to the European Molder to make, use, and sell microcellular products, but also protects any of the Molder's end customers from the possibility of infringement of Trexel Patents using such products in their own systems.

The licensed patents include 3 European Patents, 3 German Utility Models, and several U.S. patents, as well as rights to Trexel's patents in Korea, Japan, Australia, and China. According to Levi Kishbaugh, Vice President of Engineering for Trexel, "this will relieve the automotive companies of any concerns that the products that they have purchased from the Optifoam Molder will infringe Trexel patents in Europe or anywhere else in the world."

David Bernstein, President & CEO of Trexel commented, "We are pleased to have established this principle with the first Optifoam Molder. In the future, however, we will seek a Global Agreement with Sulzer Chemtech, similar to our other technology licensing agreements, in order to relieve individual molders of the burden of negotiating separate agreements in each case. "

### **About Trexel**

Trexel is the exclusive developer of the MuCell microcellular process technology and has an extensive portfolio of patents in the U.S., Canada, Europe, Japan, Korea, and Asia. Trexel's primary business is licensing the MuCell technology for the production of injection molded and extruded articles. It also provides to licensees world-class engineering support, training and other services, and the equipment and components integral to the MuCell process. In support of these activities, Trexel operates a development laboratory in its Woburn, MA facility. Other MuCell support facilities are located throughout the U.S., Europe, Japan, Korea, Hong Kong, Australia, and Singapore.

### **About the MuCell Technology**

The MuCell® Process was developed by Trexel, Inc and introduced to the injection molding market in late 1998. It is based on research performed at the Polymer Processing Lab at MIT in the 1990's. It is used worldwide to produce injection molded parts as well as some extruded products, provides significant cost savings and unique quality improvements. By introducing small, precise amounts of supercritical N<sub>2</sub> and carbon dioxide gas into the molten resin during the molding process, the MuCell process enables the otherwise unattainable production of stress free parts that maintain strict dimensional stability.

Trexel now has more than 250 licensees globally.